TY - JOUR
T1 - Anethole in cancer therapy
T2 - Mechanisms, synergistic potential, and clinical challenges
AU - Raposo, António
AU - Raheem, Dele
AU - Zandonadi , Renata Puppin
AU - Suri, Narinder
AU - Olukosi , Adeola
AU - Romão de Lima, Bernardo
AU - Carrascosa, Conrado
AU - Sharifi-Rad, Javad
AU - Bobby Ryu, Hyungseo
AU - Han, Heesup
AU - Calina, Daniela
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/11/1
Y1 - 2024/11/1
N2 - Cancer remains a major global health challenge, prompting the search for effective and less toxic treatments. Anethole, a bioactive compound found in essential oils of anise and fennel, commonly used as a food preservative, has recently garnered attention for its potential anti-cancer properties. This comprehensive review aims to systematically assess the anti-cancer effects of anethole, elucidating its mechanisms of action, pharmacokinetics, bioavailability, and synergistic potential with conventional cancer therapies. A detailed literature search was conducted across databases including PubMed, Embase, Scopus, Science Direct, Web of Science, and Google Scholar. Criteria for inclusion were experimental studies in peer-reviewed journals focusing on the anti-cancer properties of anethole. Extracted data included study design, intervention specifics, measured outcomes, and mechanistic insights. Anethole demonstrates multiple anti-cancer mechanisms, such as inducing apoptosis, causing cell cycle arrest, exhibiting anti-proliferative and anti-angiogenic effects, and modulating critical signaling pathways including NF-κB, PI3K/Akt/mTOR, and caspases. It enhances the efficacy of chemotherapeutic agents like cisplatin and doxorubicin while reducing their toxicity. In vitro and in vivo studies have shown its effectiveness against various cancers, including breast, prostate, lung, and colorectal cancers. Anethole shows significant potential as an anti-cancer agent, with its multi-faceted mechanisms of action and ability to synergize with existing chemotherapy. Further clinical research is essential to fully understand its therapeutic potential and application in oncology.
AB - Cancer remains a major global health challenge, prompting the search for effective and less toxic treatments. Anethole, a bioactive compound found in essential oils of anise and fennel, commonly used as a food preservative, has recently garnered attention for its potential anti-cancer properties. This comprehensive review aims to systematically assess the anti-cancer effects of anethole, elucidating its mechanisms of action, pharmacokinetics, bioavailability, and synergistic potential with conventional cancer therapies. A detailed literature search was conducted across databases including PubMed, Embase, Scopus, Science Direct, Web of Science, and Google Scholar. Criteria for inclusion were experimental studies in peer-reviewed journals focusing on the anti-cancer properties of anethole. Extracted data included study design, intervention specifics, measured outcomes, and mechanistic insights. Anethole demonstrates multiple anti-cancer mechanisms, such as inducing apoptosis, causing cell cycle arrest, exhibiting anti-proliferative and anti-angiogenic effects, and modulating critical signaling pathways including NF-κB, PI3K/Akt/mTOR, and caspases. It enhances the efficacy of chemotherapeutic agents like cisplatin and doxorubicin while reducing their toxicity. In vitro and in vivo studies have shown its effectiveness against various cancers, including breast, prostate, lung, and colorectal cancers. Anethole shows significant potential as an anti-cancer agent, with its multi-faceted mechanisms of action and ability to synergize with existing chemotherapy. Further clinical research is essential to fully understand its therapeutic potential and application in oncology.
KW - Anethole
KW - Apoptosis
KW - Foods
KW - Chemotherapy
KW - Anti-cancer mechanisms
KW - Signaling pathways
UR - https://www.scopus.com/pages/publications/85204573279
UR - https://www.scopus.com/inward/citedby.url?scp=85204573279&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2024.117449
DO - 10.1016/j.biopha.2024.117449
M3 - Review Article
SN - 1950-6007
VL - 180
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
IS - November 2024
M1 - 117449
ER -